The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus
- PMID: 10391113
- DOI: 10.1007/s000110050456
The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease most prevalent in women between the ages of twenty and sixty. Successful treatment remains challenging due to a lack of understanding of the underlying mechanisms and multiple symptoms ranging from skin rashes to glomerulonephritis. The pathogenesis of SLE has been linked to a B-cell hyperproliferation unique to afflicted patients. These B-cells generate large quantities of IgG autoantibodies, ultimately capable of leading to lupus nephritis and renal failure. The significance of cytokines in SLE and in murine lupus, a related disease in mice, has been debated, particularly with respect to B-cell activity. Potential roles of auto-regulatory and inflammatory cytokines have been investigated. In particular, IL-6 and IL-10 have been shown to be key factors in regulating autoantibody-secreting B-cell activity in lupus. Here, we will provide a critical overview of our current knowledge of the regulatory roles of these two cytokines in SLE.
Similar articles
-
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.J Exp Med. 1995 Mar 1;181(3):839-44. doi: 10.1084/jem.181.3.839. J Exp Med. 1995. PMID: 7869046 Free PMC article.
-
[Cytokines and lupus].Ann Med Interne (Paris). 1996;147(7):480-4. Ann Med Interne (Paris). 1996. PMID: 9092358 Review. French.
-
B cell hyperactivity is a function of T cell derived cytokines in systemic lupus erythematosus.J Rheumatol. 1993 Nov;20(11):1885-91. J Rheumatol. 1993. PMID: 7508509
-
Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion?Lupus. 2009 Jun;18(7):575-80. doi: 10.1177/0961203309102296. Lupus. 2009. PMID: 19433456 Review.
-
Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.Immunology. 2006 Nov;119(3):296-305. doi: 10.1111/j.1365-2567.2006.02433.x. Immunology. 2006. PMID: 17067309 Free PMC article.
Cited by
-
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24. J Clin Pharmacol. 2020. PMID: 32469437 Free PMC article. Review.
-
Effects of cystamine on antioxidant activities and regulatory T cells in lupus-prone mice.J Cell Mol Med. 2013 Oct;17(10):1308-15. doi: 10.1111/jcmm.12107. Epub 2013 Aug 2. J Cell Mol Med. 2013. PMID: 23905628 Free PMC article.
-
Understanding mechanisms of hypertension in systemic lupus erythematosus.Ther Adv Cardiovasc Dis. 2016 Mar 15;11(1):20-32. doi: 10.1177/1753944716637807. Online ahead of print. Ther Adv Cardiovasc Dis. 2016. PMID: 26985016 Free PMC article. Review.
-
Obesity and cytokines in childhood-onset systemic lupus erythematosus.J Immunol Res. 2014;2014:162047. doi: 10.1155/2014/162047. Epub 2014 Mar 3. J Immunol Res. 2014. PMID: 24741576 Free PMC article.
-
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.J Clin Invest. 2016 Jun 1;126(6):2077-92. doi: 10.1172/JCI87037. Epub 2016 May 16. J Clin Invest. 2016. PMID: 27183387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical